Since the first CAR T cell therapy was approved by the FDA in 2017, we’ve witnessed what was once thought to be science fiction become a reality for patients with difficult-to-treat blood cancers. The potential for one-time treatments to offer durable responses in some patients has forced payors, providers, patients and manufacturers to confront some fundamental questions. Is the U.S. insurance system set up to finance these treatments? What are some potential payment models that can account for the financial risk incurred by payors? How accessible will these treatments be for patients? What role will providers play? This moderated panel will bring together diverse perspectives to consider these questions and offer insights for how we can create an environment that is conducive to the delivery of CAR T cell therapy to those patients who stand to benefit.